Introduction: Severe pneumonia progresses rapidly, so early assessment of the severity and prognosis is crucial for reducing mortality rates.
Objective: We explore the role of serum microRNA-24 (miR-24) and microRNA-223 (miR-223) in the prognosis of severe pneumonia.
Methods: There were a total of 96 patients with general pneumonia, 94 patients with severe pneumonia, and 93 healthy people, who were enrolled in this study. The levels of serum miR-24 and miR-223 were detected by real-time fluorescent quantitative PCR in all groups.
Results: The serum miR-223 level in the severe group was higher than that in the common group and the control group, and the miR-24 level was lower than that in the common group and the control group (P< 0.05). The serum miR-223 levels and APACHEII scores in the death group were higher than those in the survival group on the first, third, and seventh day after admission, while the miR-24 levels were lower than those in the survival group (P< 0.05). The proportion of patients with mechanical ventilation in the death group was higher than that in the survival group (P< 0.05). The level of serum miR-24 was negatively correlated with APACHEII score and mechanical ventilation in patients who died of severe pneumonia (P< 0.05), and miR-223 was positively correlated with APACHEII score and mechanical ventilation (P< 0.05). The AUC predicted by serum miR-24, miR-223, and APACHEII scores alone and jointly were 0.867, 0.839, 0.791, and 0.952, respectively. MiR-24 and miR-223 are protective and independent risk factors for mortality in severe pneumonia patients, respectively (P< 0.05). MiR-24 was a protective factor affecting the death of patients with severe pneumonia, and miR-223 was an independent risk factor affecting the death of patients with severe pneumonia (P< 0.05).
Conclusion: The combination of serum miR-24 and miR-223 levels on the first day after admission and APACHEII score can effectively predict prognosis.
Keywords: severe pneumonia, micro RNA-24, micro RNA-223, prognosis